Valuation: Erasca, Inc.

Market Cap 5.24B 4.69B 4.33B 3.92B 7.33B 499B 7.44B 51.65B 20.61B 261B 19.66B 19.24B 827B P/E 2026 *
-15.1x
P/E 2027 * -22.8x
Enterprise Value 4.39B 3.93B 3.63B 3.28B 6.14B 418B 6.24B 43.29B 17.27B 219B 16.48B 16.13B 693B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.04%
Yield 2026 *
-
Yield 2027 * -
1 day-0.93%
1 week+3.38%
Current month+2.18%
1 month+6.02%
3 months-17.51%
6 months+51.31%
Current year+302.69%
1 week 13.44
Extreme 13.44
15.47
1 month 13.1
Extreme 13.1
16.2
Current year 3.36
Extreme 3.36
24.28
1 year 2.1
Extreme 2.105
24.28
3 years 1.01
Extreme 1.01
24.28
5 years 1.01
Extreme 1.01
24.28
10 years 1.01
Extreme 1.01
24.47
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2019
Director of Finance/CFO 43 07/01/2021
Chief Tech/Sci/R&D Officer 66 10/08/2026
Director TitleAgeSince
Chairman 54 01/10/2018
Director/Board Member 79 01/06/2018
Director/Board Member 58 02/07/2018
Date Insider Type Main position Quantity % Market Cap. Importance
10/8/26 Free

Chief Technology Officer

1,300,000 0.3745%
26/6/26 Free

Director

29,888 0.0096%
1/4/26 Exercice

General Counsel

240,000 0.0772%
Change 5-day change 1-year change 3-year change Capi.($)
-0.93%+3.38%+513.93%+652.76% 5.29B
+0.34%-3.03%+37.45%+61.06% 64.14B
+0.98%+2.26%+12.91%+82.98% 55.53B
+1.75%+2.76%+12.38%+103.69% 53.03B
-1.43%-0.57%+26.10%+52.86% 45.99B
-0.48%-3.86%+17.27%+117.99% 42.45B
+0.82%-2.06%+227.09%+922.41% 40.45B
-0.26%-4.20%+10.86%+45.18% 32.25B
-2.07%+44.58%+102.84%+88.74% 34.47B
-2.72%-8.79%+22.58%-5.63% 24.23B
Average -0.40%+3.88%+98.34%+212.20% 39.78B
Weighted average by Cap. -0.09%+3.15%+55.44%+167.42%

Financials

2026 *2027 *
Net sales - -
Net income -322M -288M -266M -241M -450M -30.64B -457M -3.17B -1.27B -16.04B -1.21B -1.18B -50.79B -228M -204M -189M -171M -319M -21.73B -324M -2.25B -897M -11.37B -856M -838M -36.02B
Net Debt -849M -760M -701M -635M -1.19B -80.81B -1.21B -8.37B -3.34B -42.29B -3.18B -3.12B -134B -762M -682M -629M -570M -1.07B -72.54B -1.08B -7.51B -3B -37.96B -2.86B -2.8B -120B
Projected Income Statement - Annual - Erasca, Inc.
Logo Erasca, Inc.
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Employees
103
Date Price Change Volume
29/10/26 US$14.98 -0.93% 2,250,279
28/10/26 US$15.12 -0.66% 3,412,302
27/10/26 US$15.22 +1.53% 5,825,747
26/10/26 US$14.99 +4.17% 6,466,122
23/10/26 US$14.39 +2.49% 3,499,957
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Erasca, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
14.98USD
Average target price
24.11USD
Spread / Average Target
+60.96%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Erasca, Inc.
  1. Stock Market
  2. Stocks
  3. ERAS Stock